Progressive Corporation/ US7433151039 /
2024-04-26 10:10:00 PM | Chg. -2.04 | Volume | Bid11:56:13 PM | Ask11:56:13 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
208.03USD | -0.97% | 2.63 mill. Turnover: 391.57 mill. |
204.50Bid Size: 100 | 210.90Ask Size: 100 | 121.84 bill.USD | 0.19% | 31.47 |
GlobeNewswire
04-25
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Re...
GlobeNewswire
04-24
Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society...
GlobeNewswire
04-22
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Snap One Ho...
GlobeNewswire
04-22
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients i...
GlobeNewswire
04-19
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Scleros...
GlobeNewswire
04-18
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with B...
GlobeNewswire
04-18
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple ...
GlobeNewswire
04-18
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting...
GlobeNewswire
04-18
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the P...
GlobeNewswire
04-17
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American ...
GlobeNewswire
04-16
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
04-15
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatm...
GlobeNewswire
04-15
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Snap One Ho...
GlobeNewswire
04-15
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis...
GlobeNewswire
04-11
PyroGenesis Announces That Lab Strength Tests Achieve 45% Above Target for Green Cement Additive Pro...